TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours

Pharmaceutical products
London (UKI)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The Royal Marsden NHS Foundation Trust: "Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityThe Royal Marsden NHS Foundation TrustScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: The Royal Marsden NHS Foundation Trust
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for The Royal Marsden NHS Foundation Trust. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
2Bids / Report
80% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 16 active published awards; 5 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityThe Royal Marsden NHS Foundation Trust
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published22 Jan 2021, 14:31 GMT
Last source update22 Jan 2021, 14:31 GMT
Recurring procurementNot published
ClassificationPharmaceutical products
Delivery area
London (UKI)
OCIDocds-h6vhtk-028c9a
What is being bought
Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours
What changed
From the official release history
  1. Status changed to complete
    22 Jan 2021, 14:31 GMT
  2. Official notice release published
    22 Jan 2021, 14:31 GMT
  3. Buyer information updated
    22 Jan 2021, 14:31 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    The Royal Marsden Hospital NHS Foundation Trust needs to purchase 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    22 Jan 2021, 14:31 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 22 Jan 2021, 00:00 GMT · £4,500,000
Commercial outcome and competition
Awards
Advanced Accelerator Application
Not published · Not published · active
Contracts
Contract
£4,500,000 · signed 22 Jan 2021, 00:00 GMT · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

The Royal Marsden NHS Foundation Trust

Contracting authority GB-FTS-2920
View buyer profile

  • The Royal Marsden NHS Foundation Trust
    buyer

    Unit G3, Harbour Yard, Chelsea Harbour, London, UKI, SW10 0XD
    tenders@chelwest.nhs.uk

  • Advanced Accelerator Application
    supplier

    London, UKI

  • High Court
    reviewBody

    London
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationale177Lu- Dotatate is used to treat patients with neuroendocrine tumours; currently this is the only licensed product on the market to treat this tumour and AAA is the sole distributor in the UK.